Literature DB >> 8359294

Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50--effect of smoking and extent of disease.

C Bergmark1, M A Mansoor, J Swedenborg, U de Faire, A M Svardal, P M Ueland.   

Abstract

Moderate hyperhomocysteinemia may be a risk factor for atherosclerotic peripheral vascular disease (PVD). In order to develop PVD at an early age risk factors are more strongly expressed and hyperhomocysteinemia may be one such factor. Homocysteine is derived from methionine and is metabolised by cystathionine-synthase to cystathionine or remethylated to methionine. Cystathionine-synthase activity is dependent on vitamin B6 while the remethylation of homocysteine is dependent on vitamin B12 and folate. The present study analyses homocysteine in patients operated on for lower extremity ischaemia before the age of 50. Homocysteine before and after loading with methionine, vitamin B6, B12 and folate were measured at follow-up. The patients were compared to age- and sex-matched controls. Significantly more patients than controls had hyperhomocysteinemia, 16/58 vs. 4/65, defined as fasting total homocysteine above 18.6 mumol/l. Loading with methionine did not further discriminate between patients and controls. Smoking patients had higher levels of homocysteine than non-smoking patients or smoking and non-smoking controls. Smoking patients also had lower levels of vitamin B6. When comparing patients with suprainguinal, infrainguinal and multilevel disease the highest homocysteine levels were seen in the latter group. Also, in this group smoking patients had higher homocysteine levels. Multivariate analysis revealed that homocysteine was associated with low levels of vitamin B12, folate and smoking. Smoking therefore seems to be connected to increased homocysteine levels in patients with early development of atherosclerosis, partly explained by decreased levels of B6, B12 and folate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8359294     DOI: 10.1016/s0950-821x(05)80255-5

Source DB:  PubMed          Journal:  Eur J Vasc Surg        ISSN: 0950-821X


  8 in total

1.  Circulating immune complexes and complement C4 null alleles in patients in patients operated on for premature atherosclerotic peripheral vascular disease.

Authors:  S Nityanand; L Truedsson; A Mustafa; C Bergmark; A K Lefvert
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

2.  [A young patient with multiple arterial occlusions].

Authors:  C Panzere; A Brieke; B Bräuer; F Eggemann; H M Becker; P Dieterle
Journal:  Med Klin (Munich)       Date:  1998-05-15

3.  Hyperhomocysteinaemia and premature coronary artery disease in the Chinese.

Authors:  M A Mansoor
Journal:  Heart       Date:  1997-04       Impact factor: 5.994

4.  Hyperhomocysteinaemia is an independent risk factor for peripheral arterial disease in a Chinese Han population.

Authors:  Dan Rong; Jie Liu; Xin Jia; Daniah Al-Nafisee; Senhao Jia; Guoyi Sun; Yue Li; Weihang Lu; Haifeng Li; Hongpeng Zhang; Xiaohui Ma; Jiang Xiong; Xiaoping Liu; Raouf A Khalil; Wei Guo
Journal:  Atherosclerosis       Date:  2017-05-05       Impact factor: 5.162

5.  The Hordaland Homocysteine Studies.

Authors:  P M Ueland; O Nygård; S E Vollset; H Refsum
Journal:  Lipids       Date:  2001       Impact factor: 1.880

6.  Hyperhomocysteinaemia and premature coronary artery disease in the Chinese.

Authors:  Y I Lolin; J E Sanderson; S K Cheng; C F Chan; C P Pang; K S Woo; J R Masarei
Journal:  Heart       Date:  1996-08       Impact factor: 5.994

7.  Acute coronary syndrome with large thrombus successfully managed with no-stenting revascularization based on intravascular imaging in a patient with hyperhomocysteinemia: a case report.

Authors:  Keisuke Shoji; Kenji Yanishi; Noriyuki Wakana; Naohiko Nakanishi; Kan Zen; Takeshi Nakamura; Takeshi Shirayama; Satoaki Matoba
Journal:  J Med Case Rep       Date:  2020-11-09

8.  Effect of Folic Acid therapy on Homocysteine Level in patients with Atherosclerosis or Buerger's Disease and in Healthy individuals: A clinical trial.

Authors:  Mohammad Hadi Saeed Modaghegh; Hassan Ravari; Mohammad Zare Haghighi; Ata'ollah Rajabnejad
Journal:  Electron Physician       Date:  2016-10-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.